Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 4Phase 4 1Phase 3 1

Status

Unknown 4

Sponsor Class

OTHER 318NIH 82INDUSTRY 72NETWORK 43OTHER_GOV 4UNKNOWN 2

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Gastrointestinal 1

Conditions

Breast Neoplasms 55Carcinoma, Non-Small-Cell Lung 33Stomach Neoplasms 28Colorectal Neoplasms 26Small Cell Lung Carcinoma 19Lung Neoplasms 18Rectal Neoplasms 16Pancreatic Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Carcinoma, Hepatocellular 11Recurrence 10Leukemia, Myeloid, Acute 10Melanoma 9Esophageal Squamous Cell Carcinoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Head and Neck Neoplasms 7Hodgkin Disease 6Cholangiocarcinoma 6Adenocarcinoma of Lung 6Squamous Cell Carcinoma of Head and Neck 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Germ Cell and Embryonal 5Multiple Myeloma 5

Interventions

spartalizumab 1ribociclib 1camrelizumab 1Nivolumab 1Irinotecan 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Sarcoma × Clear all
NCT05189483 2024-02-07

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Henan Cancer Hospital

Phase 2 Unknown
40 enrolled
Sarcoma

Sarcoma

NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

NCT03096912 2017-10-25

A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
30 enrolled
Sarcoma

Lipoma, Liposarcoma, Sarcoma, Liposarcoma, Myxoid

NCT01380275 2014-09-25

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Sarcoma

Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡